FDA Recognition Of Orphan Drug Exclusivity, Period

No definition available.

Name:	jazz_FDARecognitionOfOrphanDrugExclusivityPeriod
Namespace Prefix:	jazz_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

FDA Stay Of Approval Period

+ References

No definition available.

+ Details

Name:	jazz_FDAStayOfApprovalPeriod
Namespace Prefix:	jazz_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Infringed Patents Suit, Number Of Patents

+ References

No definition available.

+ Details

Name:	jazz_InfringedPatentsSuitNumberOfPatents
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Patents, Paragraph IV Certification Notice Filed

+ References

No definition available.

+ Details

Name:	jazz_NumberOfPatentsParagraphIVCertificationNoticeFiled
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Royalty Rate For Sales To Be Received

+ References

No definition available.

+ Details

Name:	jazz_RoyaltyRateForSalesToBeReceived
Namespace Prefix:	jazz_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_LitigationReserveCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount awarded to other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process.

+ References

+ Details

Name:	us-gaap_LitigationSettlementLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The total number of new claims filed pertaining to a loss contingency during the period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

+ Details

Name:	us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_LitigationCaseAxis=jazz_XyremAntitrustLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=jazz_AvadelPharmaceuticalsPlcLawsuitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=jazz_LumryzProductForNarcolepsyIndicationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=jazz_AvadelMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=jazz_LumryzProductForNonNarcolepsyIndicationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=jazz_LumryzProductForNonNarcolepsyIndicationsUnpermittedNetSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=jazz_LupinLawsuitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=jazz_XywavMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=jazz_TevaLawsuitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=jazz_DefitelioPatentLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) $ in Thousands								1 Months Ended						3 Months Ended	9 Months Ended	29 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Mar. 01, 2028	Oct. 21, 2025 USD ($)	Oct. 01, 2025	Apr. 16, 2025	Apr. 07, 2025 USD ($)	Feb. 15, 2023 litigationCase	Jun. 22, 2022 litigationCase	Aug. 31, 2025 patent	Jul. 31, 2025 patent	Mar. 31, 2023 patent	Feb. 28, 2023 patent	Jul. 31, 2021 patent	Jun. 30, 2021 patent	Sep. 30, 2025 USD ($)	Sep. 30, 2025 USD ($)	Feb. 29, 2028	Dec. 31, 2024 USD ($)	Nov. 30, 2022 patent
Loss Contingencies [Line Items]
Accrued litigation settlement														$ 90,000	$ 90,000		$ 0
Xyrem Antitrust Litigation
Loss Contingencies [Line Items]
Settlement amount					$ 145,000
Litigation expense														61,500	233,500
Avadel Litigation
Loss Contingencies [Line Items]
Accrued litigation settlement														$ 90,000	$ 90,000
Avadel Litigation \| Subsequent Event
Loss Contingencies [Line Items]
Settlement amount		$ 90,000
Avadel Litigation \| Lumryz Product for Narcolepsy Indications \| Subsequent Event \| Maximum \| Avadel
Loss Contingencies [Line Items]
Royalty rate for sales to be received			3.85%
Avadel Litigation \| Lumryz Product for Narcolepsy Indications \| Subsequent Event \| Minimum \| Avadel
Loss Contingencies [Line Items]
Royalty rate for sales to be received			3.75%
Avadel Litigation \| Lumryz Product for Non-Narcolepsy Indications \| Maximum \| Forecast \| Avadel
Loss Contingencies [Line Items]
Royalty rate for sales to be received	10.00%
Avadel Litigation \| Lumryz Product for Non-Narcolepsy Indications \| Minimum \| Forecast \| Avadel
Loss Contingencies [Line Items]
Royalty rate for sales to be received	9.50%
Avadel Litigation \| Lumryz Product for Non-Narcolepsy Indications, Unpermitted Net Sales \| Forecast \| Avadel
Loss Contingencies [Line Items]
Royalty rate for sales to be received																80.00%
Lupin Lawsuit
Loss Contingencies [Line Items]
Number of patents, paragraph IV certification notice filed \| patent													10
Infringed patents suit, number of patents \| patent												10						2
FDA stay of approval period (in months)												30 months
Number of lawsuits filed \| litigationCase						2	2
Lupin Lawsuit \| Xywav
Loss Contingencies [Line Items]
FDA recognition of orphan drug exclusivity, period (in years)													7 years
Teva Lawsuit
Loss Contingencies [Line Items]
Infringed patents suit, number of patents \| patent										13
FDA stay of approval period (in months)								30 months		30 months
Infringed patents suit, number of patents \| patent								14	14		13
Defitelio Patent Litigation
Loss Contingencies [Line Items]
FDA stay of approval period (in months)				30 months